Inhibiting NLRP3 using the small molecule BAY-117082 effectively reduces OSCC cell viability, suppresses inflammasome activation (including ASC, caspase-1, IL-1β, and IL-18), promotes pro-apoptotic markers (e.g., Bax, Bad, p53) while downregulating Bcl-2, and significantly decreases tumor burden in xenograft models (Scuderi et al., 2021). This evidence concerns the gene NLRP3 and neoplasm.